FIELD: medicine, ophthalmology. SUBSTANCE: the suggested preparation includes glycoprotein and pharmaceutically acceptable carrier. Glycoprotein obtained out of mammalian blood serum due to isoelectric focusing in pH gradient at selecting necessary fraction, dissolved in saturated (100%) solution of ammonium sulfate, has got isoelectric point within pH ranged 4.5-5.1 and apparent molecular weight ranged 10-37 kDa and, probably, calcium chloride at the following ratio of components, weight%: serumal glycoprotein 1•10-16÷1•10-9; calcium chloride 0- 0.01; carrier - the rest. The suggested innovation should be applied due to corneal instillations 2-7 times for 10-15 d both either individually or together with other preparations. Ophthalmological preparation applied in this innovation leads to forming milder corneal scar and decreases the risk of severe complications development. EFFECT: higher efficiency. 11 cl, 1 dwg, 6 tbl
Title | Year | Author | Number |
---|---|---|---|
OPHTHALMIC AGENT FOR REGENERATION OF CORNEA OF THE EYE | 2016 |
|
RU2646804C1 |
OPHTHALMOLOGICAL MEDICINAL AGENT AND METHOD FOR TREATMENT OF RETINA DISEASE, PATHOLOGICAL STATE AND INJURY | 2003 |
|
RU2232586C1 |
NEW CLASS OF PHYSIOLOGICALLY ACTIVE GLYCOPROTEINS | 2000 |
|
RU2223781C2 |
PHARMACEUTICAL COMPOSITION FOR LOCAL APPLICATION IN TREATING INFLAMMATORY EYE DISEASES AND METHOD FOR USING IT | 2012 |
|
RU2508123C1 |
USE IN THERAPY OF A STERILE AQUEOUS OPHTHALMIC SOLUTION | 2016 |
|
RU2741912C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING EYE INFECTIONS P. Aeruginosa CONTAINING RECOMBINANT LYSOZYME | 2011 |
|
RU2548803C2 |
OPHTHALMIC GEL COMPOSITION FOR TREATING CONJUNCTIVITIS, BLEPHARITIS, KERATITIS CORNEAL EROSION ASSOCIATED WITH INFLAMMATORY EYE DISEASES OF NON-INFECTIOUS OR POST-INFECTIOUS ETIOLOGY AND ALLERGIC LESIONS OF OCULAR SURFACE | 2014 |
|
RU2582284C1 |
MEDICATION FOR PREVENTION AND TREATMENT OF OPHTHALMOLOGICAL DISEASES | 2008 |
|
RU2359658C1 |
AGENT FOR TREATMENT OF EYE DISEASES AND METHOD OF ITS USE | 2016 |
|
RU2657780C2 |
COMBINED OPHTHALMIC AGENT | 2019 |
|
RU2733392C1 |
Authors
Dates
2004-01-10—Published
2001-12-17—Filed